Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence

被引:348
作者
Bonora, E [1 ]
Muggeo, M [1 ]
机构
[1] Univ Verona, Sch Med, Div Endocrinol & Metab Dis, I-37100 Verona, Italy
关键词
Type II diabetes; cardiovascular disease; fasting glucose; postprandial glucose; HbA(1c);
D O I
10.1007/s001250100020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
That cardiovascular disease occurs more frequently in patients with Type II (non-insulin-dependent) diabetes mellitus has been recognized for a long time. However, the extent to which hyperglycaemia contributes to atherosclerosis and cardiovascular disease is still not clear. Epidemiological studies published in recent years suggest that postprandial blood glucose might be an independent risk factor of cardiovascular disease. The main results of these studies, which are reviewed in this article, are that subjects from the general population with mild to moderate hyperglycaemia, following oral glucose load, but not in the fasting state, showed an increased cardiovascular risk. Furthermore, the post-challenge as well as postprandial glucose concentrations of subjects with Type II diabetes were found to be directly associated to incident cardiovascular disease independently of fasting glucose. Also, the correction of fasting hyperglycaemia or HbA(1c) or both, disregarding the specific correction of postprandial hyperglycaemia was not found to significantly reduce the incidence of cardiovascular disease in patients with Type II diabetes. Finally, the strict control of both preprandial and postprandial hyperglycaemia yielded a substantial reduction of cardiovascular disease in Type II diabetes. Trials specifically designed to address this issue are needed to determine whether postprandial hyperglycaemia plays an independent and causative role in cardiovascular disease in patients with Type II diabetes.
引用
收藏
页码:2107 / 2114
页数:8
相关论文
共 72 条
[61]   DIABETES, OTHER RISK-FACTORS, AND 12-YR CARDIOVASCULAR MORTALITY FOR MEN SCREENED IN THE MULTIPLE RISK FACTOR INTERVENTION TRIAL [J].
STAMLER, J ;
VACCARO, O ;
NEATON, JD ;
WENTWORTH, D .
DIABETES CARE, 1993, 16 (02) :434-444
[62]   Impaired glucose tolerance is a risk factor per cardiovascular disease, but not impaired fasting glucose - The Funagata diabetes study [J].
Tominaga, M ;
Eguchi, H ;
Manaka, H ;
Igarashi, K ;
Kato, T ;
Sekikawa, A .
DIABETES CARE, 1999, 22 (06) :920-924
[63]  
TURNER RC, 1993, J HYPERTENS, V11, P309
[64]   Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [J].
Turner, RC ;
Holman, RR ;
Stratton, IM ;
Cull, CA ;
Matthews, DR ;
Manley, SE ;
Frighi, V ;
Wright, D ;
Neil, A ;
Kohner, E ;
McElroy, H ;
Fox, C ;
Hadden, D .
LANCET, 1998, 352 (9131) :854-865
[65]   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].
Turner, RC ;
Holman, RR ;
Cull, CA ;
Stratton, IM ;
Matthews, DR ;
Frighi, V ;
Manley, SE ;
Neil, A ;
McElroy, K ;
Wright, D ;
Kohner, E ;
Fox, C ;
Hadden, D ;
Mehta, Z ;
Smith, A ;
Nugent, Z ;
Peto, R ;
Adlel, AI ;
Mann, JI ;
Bassett, PA ;
Oakes, SF ;
Dornan, TL ;
Aldington, S ;
Lipinski, H ;
Collum, R ;
Harrison, K ;
MacIntyre, C ;
Skinner, S ;
Mortemore, A ;
Nelson, D ;
Cockley, S ;
Levien, S ;
Bodsworth, L ;
Willox, R ;
Biggs, T ;
Dove, S ;
Beattie, E ;
Gradwell, M ;
Staples, S ;
Lam, R ;
Taylor, F ;
Leung, L ;
Carter, RD ;
Brownlee, SM ;
Fisher, KE ;
Islam, K ;
Jelfs, R ;
Williams, PA ;
Williams, FA ;
Sutton, PJ .
LANCET, 1998, 352 (9131) :837-853
[66]  
*U GROUP DIAB PROG, 1982, DIABETES S5, V3, P1
[67]  
*WHO, 1985, WHO CRIT TECHN REP S, V727
[68]   Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo [J].
Williams, SB ;
Goldfine, AB ;
Timimi, FK ;
Ting, HH ;
Roddy, MA ;
Simonson, DC ;
Creager, MA .
CIRCULATION, 1998, 97 (17) :1695-1701
[69]   Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose [J].
Wolever, TMS ;
Chiasson, JL ;
Csima, A ;
Hunt, JA ;
Palmason, C ;
Ross, SA ;
Ryan, EA .
DIABETES CARE, 1998, 21 (03) :336-340
[70]   A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes [J].
Wolffenbuttel, BHR ;
Landgraf, R .
DIABETES CARE, 1999, 22 (03) :463-467